title: Treatment Patterns and Glycemic Control in Older Adults with Type 2 Diabetes Mellitus Receiving Only Oral Antidiabetes Drugs in China.
abstract: BACKGROUND
  Only a few studies have reported the use of oral antidiabetes drugs (OADs) for treating older adults with type 2 diabetes mellitus (T2DM) in China. This study assessed the status of OAD therapy and relevant factors associated with OAD treatment patterns and glycemic control among older patients.
  
  
  METHODS
  We conducted a noninterventional, observational, cross-sectional, multicenter study, which was initiated by the Chinese Diabetes Society, in which 9,872 outpatients with T2DM were recruited who received OADs only. Current antidiabetes treatment regimens and related clinical data were collected from patients' self-reporting and medical records. Participants were divided into two groups: ≥65 years and <65 years. All data were tabulated, and statistical analyses were performed using SPSS version 16 software (SPSS Inc., Chicago, IL).
  
  
  RESULTS
  Insulin secretagogues (52.6%): sulfonylureas (SU) (26.6%) and glinides (26.0%) were commonly used as monotherapy in those ≥65 years. The most popular OAD pattern was dual combination therapy (46.8%), with SU plus glucosidase inhibitors (25.1%) being most common in older participants. Age, diabetes duration, body mass index, achieving the glycemic control targets, and hypoglycemia were influencing factors to those ≥65 years in diverse treatment pattern models (P < 0.05). Older patients receiving OADs with triple or more combination treatment and complications were more likely to have substandard glycemic control (hemoglobin A1c level ≥7%).
  
  
  CONCLUSIONS
  The pattern of OADs alone in older adults with T2DM was significantly different from those <65 years in China. A comprehensive OAD treatment pattern or insulin combination may be necessary for better glycemic control in older patients with multiple combinations of OADs or complications.
authors.affiliation: 1 Department of Endocrinology and Metabolism, Peking University People's Hospital , Beijing, China .
authors.forename: Lihua
authors.initials: L
authors.lastname: Zhang
authors.affiliation: 1 Department of Endocrinology and Metabolism, Peking University People's Hospital , Beijing, China .
authors.forename: Linong
authors.initials: L
authors.lastname: Ji
authors.affiliation: 2 Department of Endocrinology and Metabolism, Beijing Hospital , Beijing, China .
authors.forename: Lixin
authors.initials: L
authors.lastname: Guo
authors.affiliation: 3 Department of Endocrinology and Metabolism, Chinese PLA General Hospital , Beijing, China .
authors.forename: Juming
authors.initials: J
authors.lastname: Lu
authors.affiliation: 4 Department of Endocrinology and Metabolism, Sichuan University West China Hospital , Chengdu, China .
authors.forename: Haoming
authors.initials: H
authors.lastname: Tian
authors.affiliation: 5 Department of Endocrinology and Metabolism, Nanjing Drum Tower Hospital , Jiangsu, China .
authors.forename: Dalong
authors.initials: D
authors.lastname: Zhu
authors.affiliation: 6 Department of Endocrinology and Metabolism, Peking Union Medical College Hospital , Beijing, China .
authors.forename: Xiaoping
authors.initials: X
authors.lastname: Xing
authors.affiliation: 7 Department of Endocrinology and Metabolism, The Third Affiliated Hospital of Sun Yat-sen University , Guangzhou, China .
authors.forename: Jian Ping
authors.initials: JP
authors.lastname: Weng
authors.affiliation: 8 Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People's Hospital , Shanghai, China .
authors.forename: Weiping
authors.initials: W
authors.lastname: Jia
mesh_terms: D000284:Administration, Oral; D000367:Age Factors; D000368:Aged; D001786:Blood Glucose / Q000187:drug effects*; D002681:China; D003430:Cross-Sectional Studies; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D006442:Glycated Hemoglobin / Q000187:drug effects*; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D007328:Insulin / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D013453:Sulfonylurea Compounds / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; D013453:Sulfonylurea Compounds; C517652:hemoglobin A1c protein, human